日本的抗體治療藥市場:各產品類型，各適應疾病，各給藥途徑，各終端用戶，各地區，機會，預測，2019年～2033年

預計在預測期內（2025-2033 年），日本抗體治療市場規模將以 10% 的複合年增長率增長，從 2025 年的 193.3 億美元增長至 2033 年的 414.4 億美元。受近期技術趨勢和對有效治療解決方案的迫切需求的推動，日本治療性抗體市場正在經歷強勁增長。市場擴張的主要因素之一是癌症和心血管疾病等慢性疾病的發生率不斷增加，進而促使製造業業務的增加。

例如，Epkinly™（通用名：epcolitamab）已獲得厚生勞動省的批准，是日本第一個也是唯一一個獲批用於治療某些復發或難治性大B細胞淋巴瘤（LBCL）成年患者的T細胞介導雙特異性抗體。這包括瀰漫大 B 細胞淋巴瘤 (DLBCL)、高級別 B 細胞淋巴瘤 (HGBCL)、原發性縱隔大 B 細胞淋巴瘤 (PMBCL) 和 3B 級濾泡性淋巴瘤 (FL3B)。 Epcolitamab 是 Genmab 和 AbbVie 腫瘤學合作的一部分。

本報告提供日本的抗體治療藥市場相關調查，提供市場概要，以及各產品類型，各適應疾病，各給藥途徑，各終端用戶，各地區趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 日本的抗體治療藥市場預測，2019年～2033年

• 市場規模分析與預測
• 市場佔有率分析與預測
• 2025年市場地圖分析
  • 各產品類型
  • 各適應疾病
  • 各給藥途徑
  • 各終端用戶
  • 各地區

第5章 需求供給分析

第6章 價值鏈分析

第7章 波特的五力分析

第8章 大環境分析

第9章 價格分析

第10章 市場動態

• 市場促進因素
• 市場課題

第11章 市場趨勢與發展

第12章 法規情形

第13章 臨床試驗概要

第14章 案例研究

第15章 競爭情形

• 市場領導前五名的競爭矩陣
• 參與企業前五名的SWOT分析
• 市場前10名的主要企業的形勢
  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Amgen Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca plc
  • Eli Lilly and Company

第16章 策略性建議

第17章 關於調查公司·免責聲明

Japan antibody therapeutics market is projected to witness a CAGR of 10% during the forecast period FY2025-FY2033, growing from USD 19.33 billion in FY2025 to USD 41.44 billion in FY2033. Japan market for antibody therapeutics has grown significantly because of recent developments in technology and the urgent need for effective therapeutic solutions. One of the main reasons for driving market expansion is the increasing frequency of chronic diseases such as cancer and cardiovascular disorders, which has increased manufacturing operations.

For example, the Japan Ministry of Health, Labour and Welfare has granted approval to EPKINLY(TM) (epcoritamab), making it the first and only T-cell engaging bispecific antibody approved in Japan for the treatment of adult patients with certain relapsed or refractory large B-cell lymphoma (LBCL) types. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B), after two or more prior lines of systemic therapy. Epcoritamab is co-developed by Genmab and AbbVie under their oncology collaboration.

Increasing Prevalence of Chronic Diseases and Aging Population Driving Market Demand

Japan has one of the world's oldest populations, with more than 28% of its residents aged 65 and older. This demographic shift has led to a surge in age-related diseases, particularly cancer, autoimmune disorders, and neurological conditions, which are major targets for antibody therapeutics. The rising burden of these diseases is increasing the demand for monoclonal antibodies (mAbs) and polyclonal antibodies, as they offer targeted treatment with fewer side effects compared to traditional therapies. Additionally, the high prevalence of rheumatoid arthritis, multiple sclerosis, and inflammatory diseases in Japan is further driving the adoption of antibody-based treatments. For instance, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Roche's Polivy (polatuzumab vedotin) for the first-line treatment of diffuse large B-cell lymphoma (DLBCL) in combination with chemotherapy. In December 2024, Roche presented five-year follow-up data from the phase III POLARIX study, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions in previously untreated DLBCL. This approval marked a significant advancement in the antibody therapeutics space, providing a new treatment option for a disease that accounts for 30-40% of all non-Hodgkin lymphoma cases in Japan. The increasing number of such approvals is expected to propel the growth of the antibody therapeutics market, as more patients gain access to life-saving biologics.

Rising Investments and Collaborations in Antibody Drug Development

Japan's pharmaceutical sector is witnessing substantial investments and strategic collaborations to advance antibody drug discovery and development. Leading pharmaceutical firms and biotech companies are expanding their biologics research and development (R&D) activities in Japan to leverage the country's expertise in biotechnology and precision medicine. With government support for biopharmaceutical innovations, the market for antibody therapeutics is experiencing rapid expansion. For instance, in August 2023, ImmunoGen, Inc. entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ELAHERE is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRa)-positive, platinum-resistant ovarian cancer. Under the terms of the agreement, ImmunoGen received a USD 34 million upfront payment and is eligible for additional regulatory and commercial milestone payments, as well as double-digit royalties on future net sales in Japan. This collaboration underscores Takeda's commitment to bringing innovative oncology therapies to the Japanese market, addressing significant unmet medical needs.

Increasing Adoption of Subcutaneous Antibody Therapeutics for Patient Convenience

Among the different routes of administration, subcutaneous antibody therapies are gaining popularity in Japan due to greater patient convenience, reduced hospital visits, and lower healthcare costs. Intravenous (IV) infusion, the traditional method of delivering antibody drugs, often requires long hospital stays and high administration costs. However, the introduction of subcutaneous formulations has allowed patients to receive antibody-based treatments at home or in outpatient settings, improving compliance and accessibility. A major development in this segment occurred in January 2024, when Johnson & Johnson's Janssen Pharmaceuticals received approval in Japan for DARZALEX SC (daratumumab), a subcutaneous formulation of its blockbuster multiple myeloma drug. This new version offers shorter administration time and improved patient comfort compared to the intravenous form. With such advancements, subcutaneous antibody therapies are expected to gain a larger market share in Japan, particularly for chronic conditions like cancer, autoimmune diseases, and hematological disorders. As more subcutaneous antibody drugs receive regulatory approvals, the segment will continue to expand, driving overall market growth.

Future Market Scenario (FY2026 - FY2033F)

Many factors claim the growth of Japan antibody therapeutics market. Technological and infrastructural advancements give better results after the diagnosis of the disease. For instance, Astellas has committed USD 256 million to expand its antibody and cell therapy operations in both Japan and the United States. The investment will support the company's future pipeline by building two multi-modality facilities in Japan and relocating a regenerative medicine plant in Massachusetts. The expansion, which includes sites in Toyama and Tsukuba (Japan) and Massachusetts (U.S.), will enhance both R&D and manufacturing capabilities to advance the development and commercialization of Astellas' portfolio. Opportunity also lies in the increasing number of viral infections that the Japan is facing today. Promising moves of the government that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial.

Key Players Landscape and Outlook

Key players in the antibody therapeutics industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, in order to improve and broaden the use of ADCs for patients with various cancer types, the partnership combines Merck KGaA's extensive oncology knowledge and clinical development skills with Daiichi Sankyo's demonstrated ADC expertise and DXd technology. With the exception of Japan, where Daiichi Sankyo maintains exclusive rights, Daiichi Sankyo and Merck will jointly develop and market patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan globally.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Antibody Therapeutics Market Outlook, FY2019-FY2033F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product Type
    • 4.2.1.1. Monoclonal Antibodies
    • 4.2.1.2. Polyclonal Antibodies
    • 4.2.1.3. Others
  • 4.2.2. By Disease Indication
    • 4.2.2.1. Oncology
    • 4.2.2.2. Hematology
    • 4.2.2.3. Immunology
    • 4.2.2.4. Autoimmune and Inflammatory Diseases
    • 4.2.2.5. Neurology
    • 4.2.2.6. Others
  • 4.2.3. By Route of Administration
    • 4.2.3.1. Intravenous
    • 4.2.3.2. Subcutaneous
    • 4.2.3.3. Other Routes of Administration
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Long-term Care Centers
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 4.3. Market Map Analysis, FY2025
  • 4.3.1. By Product Type
  • 4.3.2. By Disease Indication
  • 4.3.3. By Route of Administration
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Landscape

13. Overview of Clinical Trials

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. AbbVie Inc.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Bristol-Myers Squibb Co.
  • 15.3.3. F. Hoffmann-La Roche Ltd.
  • 15.3.4. Johnson & Johnson Services Inc.
  • 15.3.5. Amgen Inc.
  • 15.3.6. Merck KGaA
  • 15.3.7. Novartis AG
  • 15.3.8. Pfizer Inc.
  • 15.3.9. AstraZeneca plc
  • 15.3.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Antibody Therapeutics Market, By Value, In USD Billion, FY2019-FY2033F
• Figure 2. Japan Antibody Therapeutics Market Share (%), By Product Type, FY2019-FY2033F
• Figure 3. Japan Antibody Therapeutics Market Share (%), By Disease Indication, FY2019-FY2033F
• Figure 4. Japan Antibody Therapeutics Market Share (%), By Route of Administration, FY2019-FY2033F
• Figure 5. Japan Antibody Therapeutics Market Share (%), By End-user, FY2019-FY2033F
• Figure 6. Japan Antibody Therapeutics Market Share (%), By Region, FY2019-FY2033F
• Figure 7. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 8. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 9. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 10. By End-user Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2025